[go: up one dir, main page]

PT2029130E - Derivados de alfa-aminoamida úteis no tratamento de distúrbios cognitivos - Google Patents

Derivados de alfa-aminoamida úteis no tratamento de distúrbios cognitivos Download PDF

Info

Publication number
PT2029130E
PT2029130E PT77259893T PT07725989T PT2029130E PT 2029130 E PT2029130 E PT 2029130E PT 77259893 T PT77259893 T PT 77259893T PT 07725989 T PT07725989 T PT 07725989T PT 2029130 E PT2029130 E PT 2029130E
Authority
PT
Portugal
Prior art keywords
alpha
treatment
cognitive disorders
derivatives useful
aminoamide derivatives
Prior art date
Application number
PT77259893T
Other languages
English (en)
Inventor
Patricia Salvati
Stefano Rossetti
Luca Benatti
Original Assignee
Newron Pharm Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Newron Pharm Spa filed Critical Newron Pharm Spa
Publication of PT2029130E publication Critical patent/PT2029130E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/402—1-aryl substituted, e.g. piretanide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
PT77259893T 2006-06-15 2007-06-13 Derivados de alfa-aminoamida úteis no tratamento de distúrbios cognitivos PT2029130E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP06012352A EP1870097A1 (en) 2006-06-15 2006-06-15 Alpha-aminoamide derivatives useful in the treatment of cognitive disorders

Publications (1)

Publication Number Publication Date
PT2029130E true PT2029130E (pt) 2015-10-28

Family

ID=37103353

Family Applications (1)

Application Number Title Priority Date Filing Date
PT77259893T PT2029130E (pt) 2006-06-15 2007-06-13 Derivados de alfa-aminoamida úteis no tratamento de distúrbios cognitivos

Country Status (26)

Country Link
US (1) US8741957B2 (pt)
EP (4) EP1870097A1 (pt)
JP (2) JP2009539908A (pt)
KR (1) KR20090018817A (pt)
CN (2) CN102512406B (pt)
AR (1) AR061505A1 (pt)
AU (1) AU2007260239B2 (pt)
BR (1) BRPI0712994A2 (pt)
CA (1) CA2655243C (pt)
CY (1) CY1116699T1 (pt)
DK (1) DK2029130T3 (pt)
EA (1) EA018006B1 (pt)
ES (1) ES2549113T3 (pt)
HK (1) HK1170429A1 (pt)
HR (1) HRP20151026T1 (pt)
HU (1) HUE026484T2 (pt)
IL (1) IL195906A (pt)
ME (1) ME02343B (pt)
MX (1) MX2008016017A (pt)
NZ (1) NZ573565A (pt)
PL (1) PL2029130T3 (pt)
PT (1) PT2029130E (pt)
RS (1) RS54324B1 (pt)
SI (1) SI2029130T1 (pt)
TW (1) TWI494293B (pt)
WO (1) WO2007144153A2 (pt)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004266494B2 (en) * 2003-08-25 2010-04-08 Newron Pharmaceuticals, Spa Alpha-aminoamide derivatives useful as anti-inflammatory agents
EP1870097A1 (en) * 2006-06-15 2007-12-26 Newron Pharmaceuticals S.p.A. Alpha-aminoamide derivatives useful in the treatment of cognitive disorders
RS53824B1 (en) 2006-06-19 2015-06-30 Newron Pharmaceuticals S.P.A. PROCESS FOR OBTAINING 2- [4- (3-AND 2-FLUOROBENZYLOXY) BENZYLAMINO] PROPANAMIDE
SI2155663T1 (en) 2007-06-15 2018-03-30 Newron Pharmaceuticals S.P.A. SUBSTITUTED 2- (2- (PHENYL) ETHYLAMINO) ALKANAMIDIC DERIVATIVES AND THEIR USE AS SODIUM AND / OR CALCIUM CHANNEL MODULATORS
KR101500962B1 (ko) 2007-12-19 2015-03-10 뉴론 파마슈티칼즈 에스. 피. 에이. 정신 장애의 치료에 유용한 알파­아미노아미드 유도체
EP2314569A1 (en) 2009-10-22 2011-04-27 Merck Patent GmbH Novel polymorphic forms of (S)-2-[4-(3-Fluoro-benzyloxy)-benzylamino]-propionamide mesylate salt and processes of manufacturing thereof
WO2011055383A2 (en) 2009-11-06 2011-05-12 Lyka Labs Limited Intranasal delivery to improve the performance of children suffering from dyslexia
US8255838B2 (en) * 2010-01-15 2012-08-28 Synopsys, Inc. Etch-aware OPC model calibration by using an etch bias filter
WO2011098456A1 (en) * 2010-02-09 2011-08-18 Merck Serono S.A. Safinamide in the treatment of dyskinesia
ME02509B (me) 2010-04-27 2017-02-20 Newron Pharm Spa Proces za proizvodnju metansulfonatnih soli ralfinamida ili njihovih r-enantiomera
US12201676B2 (en) 2011-03-18 2025-01-21 Dr Healthcare España, S.L. Composition comprising diamine oxidase for use in the treatment or prevention of fibromyalgia or chronic fatigue syndrome
US10039777B2 (en) 2012-03-20 2018-08-07 Neuro-Lm Sas Methods and pharmaceutical compositions of the treatment of autistic syndrome disorders
ES2426539B1 (es) * 2012-04-18 2014-09-09 Dr Healthcare España, S. L. Uso de la diaminooxidasa para el tratamiento o la prevención del trastorno por deficit de atencion con hiperactividad (adhd)
KR101420218B1 (ko) * 2012-06-13 2014-07-17 이우일 생리적안정도 측정 시스템 및 그 방법
CN104546747A (zh) * 2014-11-20 2015-04-29 美吉斯制药（厦门）有限公司 一种含有甲磺酸沙芬酰胺的药物组合物及其制备方法
CN105456214A (zh) * 2015-12-30 2016-04-06 蔡惠文 甲磺酸沙芬酰胺片
KR101970099B1 (ko) * 2018-02-07 2019-04-17 한국과학기술연구원 척수 손상의 예방 및 치료용 조성물
KR102005019B1 (ko) * 2018-04-04 2019-07-31 한국과학기술연구원 뇌졸중의 예방 및 치료용 조성물
WO2019222339A1 (en) * 2018-05-15 2019-11-21 Tran Lloyd Hung Loi Therapeutic agent composition and method of use, for treatment of mild cognitive impairment, depression, and psychological disorders
JP7514859B2 (ja) * 2019-05-21 2024-07-11 ハー・ルンドベック・アクチエゼルスカベット パーキンソン病の治療に使用するための新規なカテコールアミンプロドラッグ
WO2024173804A1 (en) * 2023-02-17 2024-08-22 Rowan University Automated detection of cognitive conditions

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1140748A (en) 1966-06-23 1969-01-22 Ici Ltd New carboxylic acid derivatives
US3795739A (en) 1972-02-14 1974-03-05 Hoffmann La Roche Treatment of parkinson disease
US4049663A (en) 1972-06-06 1977-09-20 Allen & Hanburys Limited Ethylene diamine derivatives
FR2480747A1 (fr) 1980-04-17 1981-10-23 Roques Bernard Derives d'acides amines et leur application therapeutique
EP0331620B1 (de) 1988-03-01 1993-08-11 Birkmayer, Walther, Prof. Dr. Mittel zur Behandlung des Parkinson-Syndroms
IL94466A (en) * 1989-05-25 1995-01-24 Erba Carlo Spa Pharmaceutical preparations containing the history of A-amino carboxamide N-phenylalkyl are converted into such new compounds and their preparation
US5221536A (en) 1990-05-07 1993-06-22 Alza Corporation Dosage form indicated for the management of abnormal posture, tremor and involuntary movement
ATE147978T1 (de) * 1992-05-27 1997-02-15 Merrell Pharma Inc Verwendung von (e) - 2 - (p -fluorophenethyl)- 3 - fluoroallylamine zur behandlung der alzheimerschen krankheit
GB9306886D0 (en) * 1993-04-01 1993-05-26 Erba Carlo Spa Substituted (arylakoxybenzyl) aminopropanamide derivatives and process for their preparation
ATE258067T1 (de) 1995-05-26 2004-02-15 Pfizer Kombinationspräparat zur behandlung der parkinsonschen krankheit, das selektive nmda- antagonisten enthält
GB9515411D0 (en) 1995-07-27 1995-09-27 Pharmacia Spa N-(4-substituted-benzyl)-2-aminolactam derivatives
GB9515412D0 (en) * 1995-07-27 1995-09-27 Pharmacia Spa 2-(4-substituted)-benzylamino-2-methyl-propanamide derivatives
EP2201945B1 (en) * 1997-11-21 2013-03-06 Purdue Neuroscience Company Use of substituted 2-aminoacetamides for treating or ameliorating anxiety
GB9727523D0 (en) 1997-12-31 1998-02-25 Pharmacia & Upjohn Spa Alpha-aminoamide derivatives useful as analgesic agents
GB9727521D0 (en) 1997-12-31 1998-02-25 Pharmacia & Upjohn Spa Substituted 2-benzylamino-2-phenyl-acetamide compounds
AU761457B2 (en) 1998-01-12 2003-06-05 Deborah Wenzel An additive composition also used as a fuel composition comprising water soluble alcohols
FI109453B (fi) 1999-06-30 2002-08-15 Orion Yhtymae Oyj Farmaseuttinen koostumus
US20020019421A1 (en) 2000-07-05 2002-02-14 Roni Biberman Compositions and therapy for substance addiction
AR044007A1 (es) * 2003-04-11 2005-08-24 Newron Pharmaceuticals Inc Metodos para el tratamiento de la enfermedad de parkinson
US20050203130A1 (en) * 2003-12-02 2005-09-15 Erik Buntinx Use of D4 and 5-HT2A antagonists, inverse agonists or partial agonists
EP1588704A1 (en) 2004-04-22 2005-10-26 Newron Pharmaceuticals S.p.A. Alpha-aminoamide derivatives useful in the treatment of restless legs syndrome and addictive disorders
GB0419199D0 (en) * 2004-08-27 2004-09-29 Curidium Ltd Methods of diagnosis
EP1870097A1 (en) * 2006-06-15 2007-12-26 Newron Pharmaceuticals S.p.A. Alpha-aminoamide derivatives useful in the treatment of cognitive disorders

Also Published As

Publication number Publication date
HRP20151026T1 (hr) 2015-10-23
AU2007260239A1 (en) 2007-12-21
SI2029130T1 (sl) 2015-11-30
JP6119068B2 (ja) 2017-04-26
EP2029130A2 (en) 2009-03-04
CN102512406B (zh) 2015-01-07
AU2007260239B2 (en) 2012-08-30
MX2008016017A (es) 2009-01-16
JP2009539908A (ja) 2009-11-19
AR061505A1 (es) 2008-09-03
CN102512406A (zh) 2012-06-27
ME02343B (me) 2016-06-20
PL2029130T3 (pl) 2016-01-29
BRPI0712994A2 (pt) 2012-03-27
ES2549113T3 (es) 2015-10-23
HK1170429A1 (en) 2013-03-01
KR20090018817A (ko) 2009-02-23
DK2029130T3 (en) 2015-11-16
WO2007144153A3 (en) 2008-03-13
TW200808696A (en) 2008-02-16
EP2343064A1 (en) 2011-07-13
EA200802306A1 (ru) 2009-06-30
US20100016437A1 (en) 2010-01-21
JP2013155186A (ja) 2013-08-15
HUE026484T2 (en) 2016-06-28
RS54324B1 (en) 2016-02-29
IL195906A0 (en) 2009-09-01
CA2655243C (en) 2015-06-02
CN101466366A (zh) 2009-06-24
IL195906A (en) 2016-02-29
EA018006B1 (ru) 2013-04-30
NZ573565A (en) 2013-01-25
EP1870097A1 (en) 2007-12-26
WO2007144153A2 (en) 2007-12-21
EP2977046A1 (en) 2016-01-27
EP2029130B1 (en) 2015-08-19
US8741957B2 (en) 2014-06-03
CA2655243A1 (en) 2007-12-21
TWI494293B (zh) 2015-08-01
CY1116699T1 (el) 2017-03-15

Similar Documents

Publication Publication Date Title
IL195906A0 (en) Alpha-aminoamide derivatives useful in the treatment of cognitive disorders
IL187168A0 (en) Improved nanobodiestm for the treatment of aggregation-mediated disorders
HK1126212A1 (en) Heterocyclic compounds and uses thereof in the treatment of sexual disorders
EP1853295A4 (en) METHOD AND COMPOSITIONS FOR TREATING GASTROINTESTINAL DISEASES
EP1940441A4 (en) COMPOSITIONS AND METHODS FOR TREATING GASTROINTESTINAL DISORDERS
EP1893216A4 (en) METHOD AND COMPOSITIONS FOR THE TREATMENT OF EYE DISEASES
GB201001047D0 (en) Methods and compositions for the treatment of neurological disorders
IL193936A0 (en) Compositions and methods for the treatment of immunoinflammatory disorders
EP1996218A4 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS
IL205578A0 (en) Aldh-2 inhibitors in the treatment of psychiatric disorders
HK1247943A1 (zh) 發育相關疾病的治療
IL191537A0 (en) Methods and compositions for the treatment of gastrointestinal disorders
ZA200806455B (en) Use of 2-imidazoles for the treatment of CNS disorders
GB0611240D0 (en) The treatment of increased sebum production
HK1146221A1 (en) Alpha-aminoamide derivatives useful in the treatment of psychiatric disorders
HK1139855A1 (en) Specific 3-heteroaryl-3-hydroxy-2-amino-propionic acid amide derivative for use in the treatment of certain cognitive disorders
GB0611241D0 (en) The treatment of increased sebum production
HK1134032A1 (en) New combination for use in the treatment of inflammatory disorders
ZA201108106B (en) Use of phthalimide derivatives in the treatment of diseases
IL192933A0 (en) Benzoisoindole derivatives for the treatment of pain
IL192877A0 (en) Use of 2-imidazoles for the treatment of cns disorders
PL1982178T3 (pl) Sposoby leczenia zaburzeń afektywnych
IL209417A0 (en) 1-amino-alkylcyclohexane derivatives for the treatment of sleep disorders
GB0710277D0 (en) Use of antivirals in the treatment of medical disorders
HK1145282A1 (en) Treatment of sleep disorders